
Where We Are Now with LEN for PrEP



announce access

priority countries

agreement and finalize

initial supply for nine

accelerated review

of LEN for PrEP

U.S. Food and Drug

Administration for

lenacapavir for HIV

twice-yearly

prevention

application to the

Agency

European Medicines

market authorization

of LEN for PrEP.

of schedule

two months ahead

